Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ASPCFOTCMKTS:HIPHNASDAQ:KTTANASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/AHIPHAmerican Premium Mining$0.00$0.00▼$0.00$6.44M2.391.82 million shsN/AKTTAPasithea Therapeutics$0.97+3.2%$1.23$0.79▼$7.50$7.22M0.542.07 million shs596,517 shsSBFMSunshine Biopharma$1.41-2.1%$1.49$1.17▼$14.00$6.42M1.35599,736 shs43,861 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%HIPHAmerican Premium Mining0.00%0.00%0.00%0.00%0.00%KTTAPasithea Therapeutics+4.96%-0.11%-42.68%-18.97%-83.93%SBFMSunshine Biopharma0.00%+2.86%+3.60%-37.12%+127.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics0.7766 of 5 stars0.02.00.00.03.01.70.6SBFMSunshine Biopharma2.7394 of 5 stars3.54.00.00.03.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASPCFAcerus Pharmaceuticals 0.00N/AN/AN/AHIPHAmerican Premium Mining 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/ASBFMSunshine Biopharma 3.00Buy$15.00963.83% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07HIPHAmerican Premium Mining$70K0.00N/AN/AN/ANaNKTTAPasithea TherapeuticsN/AN/AN/AN/A$22.46 per shareN/ASBFMSunshine Biopharma$36.23M0.18N/AN/A$1,651.69 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/AHIPHAmerican Premium MiningN/AN/A0.00N/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics-$15.96M-$10.60N/A∞N/AN/A-81.57%-74.31%8/11/2025 (Estimated)SBFMSunshine Biopharma-$4.51M-$150.88N/A∞N/A-12.82%-17.89%-14.25%8/14/2025 (Estimated)Latest ASPCF, KTTA, SBFM, and HIPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/A5/15/2025Q1 2025SBFMSunshine BiopharmaN/A-$0.44N/A-$0.44N/A$8.90 million3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASPCFAcerus PharmaceuticalsN/A0.670.34HIPHAmerican Premium MiningN/AN/AN/AKTTAPasithea TherapeuticsN/A14.8214.82SBFMSunshine BiopharmaN/A5.743.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASPCFAcerus PharmaceuticalsN/AHIPHAmerican Premium MiningN/AKTTAPasithea Therapeutics23.92%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipASPCFAcerus PharmaceuticalsN/AHIPHAmerican Premium MiningN/AKTTAPasithea Therapeutics16.30%SBFMSunshine Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableHIPHAmerican Premium Mining164.40 billionN/ANot OptionableKTTAPasithea Therapeutics37.44 million1.06 millionNot OptionableSBFMSunshine Biopharma34.56 million1.22 millionNot OptionableASPCF, KTTA, SBFM, and HIPH HeadlinesRecent News About These CompaniesSunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last YearMay 15, 2025 | accessnewswire.comSunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | finanznachrichten.deSunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | accessnewswire.comSunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comSunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 BillionApril 21, 2025 | accessnewswire.comSunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct OfferingApril 3, 2025 | accessnewswire.comThis Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2, 2025 | msn.comSunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesApril 2, 2025 | accessnewswire.comSunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2, 2025 | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2, 2025 | finance.yahoo.comSunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearApril 1, 2025 | accessnewswire.comSunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comSunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in CanadaMarch 24, 2025 | accessnewswire.comSunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | finanznachrichten.deSunshine Biopharma’s Nora Pharma acquires gastrointestinal drug rightsMarch 10, 2025 | markets.businessinsider.comSunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | accessnewswire.comSunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODTJanuary 21, 2025 | accessnewswire.comSunshine Biopharma Announces the Appointment of New Chief Commercial OfficerJanuary 15, 2025 | accesswire.comSunshine Biopharma Announces Novel Inhibitor for Sars CoronavirusDecember 9, 2024 | accesswire.comSunshine Biopharma introduces new drug, Ursodiol for management of cholestatic liver diseases, including PBCNovember 25, 2024 | pharmabiz.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASPCF, KTTA, SBFM, and HIPH Company DescriptionsAcerus Pharmaceuticals OTCMKTS:ASPCF$0.22 0.00 (0.00%) As of 07/21/2023Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.American Premium Mining OTCMKTS:HIPHAmerican Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.Pasithea Therapeutics NASDAQ:KTTA$0.97 +0.03 (+3.20%) Closing price 04:00 PM EasternExtended Trading$0.97 0.00 (-0.42%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Sunshine Biopharma NASDAQ:SBFM$1.41 -0.03 (-2.08%) Closing price 03:59 PM EasternExtended Trading$1.42 +0.01 (+0.35%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
